Loading clinical trials...

Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung Cancer | Clinical Trials | Clareo Health

UNKNOWNPHASE1/PHASE2

Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung Cancer

Dose-escalation by Hypofractionated Stereotactic Radiotherapy Simultaneous Integrated Boost IMRT for Brain Metastases in Non Small Cell Lung Cancer：A Phase I Study

NCT05588206•First People's Hospital of Hangzhou

View on ClinicalTrials.gov

Summary

The objective of this trial is to assess the safety and feasibility of delivering SBRT to patients with limited BMs (less than 10 lesions of lung cancer) by establishing the maximally tolerated dose (MTD) of SABR in 5 fractions.

Detailed Description

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histology confirmed that it was non-small cell lung cancer
•1 to 10 brain metastases detected by magnetic resonance imaging (MRI)
•A life expectancy of \>3 months according to the DS GPA.
•KPS ≥70
•Control of the primary lesions (thorax) at the time of SBRT
•2cm\<Tumor size ≤ 4 cm
•Age of 18-75 years old
•Patients must be able to undergo contrast enhanced MRI for planning
•Adequate bone marrow and organ function

Exclusion Criteria

•other malignant tumors
•Prior surgery to brain metastasis
•Prior brain radiotherapy
•Non-small cell lung cancer with more than 10 brain metastases detected by MRI
•Contraindication to receiving radiotherapy.

Locations (1)

Kaicheng Pan

Hangzhou, China

Key Dates

Start Date

January 1, 2022

Primary Completion Date

December 31, 2023

Completion Date

December 31, 2024

Last Updated

October 20, 2022

Enrollment

ESTIMATED participants

Conditions

Non Small Cell Lung CancerStage IV Non-small Cell Lung CancerBrain Metastases

Interventions

Hypofractionated Stereotactic Radiotherap

RADIATION

Contacts

Bing Xia

CONTACT

057156006382 bingxia_hzch@163.com

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

RECRUITINGPHASE2

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

NCT05692635

Brain MetastasesNonsmall Cell Lung Cancer Stage III

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 20, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung Cancer

Inclusion Criteria

Exclusion Criteria

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)